Teva Pharmaceutical has announced a collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance the global development of the anti-programmed cell death protein 1 (PD1)-Interleukin ...

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanomaFosun Pharma-Teva collaboration agreement established ...

On June 16, Teva Pharmaceutical announced a collaboration agreement with China-based Shanghai Fosun Pharmaceutical Group Co., Ltd. (better known as Fosun Pharma) to co-develop TEV-56278, which is ...

Teva now expects to have the top-line results from a study of its anti-TL1A drug, developed with Sanofi, in the fourth quarter. Teva is also testing new drugs for cancer, asthma and schizophrenia.

Under the agreement, Royalty Pharma will provide Teva up to $100 million to fund ongoing development costs for olanzapine LAI (TEV-‘749), and Royalty Pharma and Teva have a mutual option to ...

FTC opens investigation into Teva, escalating patent fight with pharma industry Democrats have accused drug companies of “junk patent listings,” arguing that the industry is blocking generic ...

Teva said it earned $1.00 per diluted share excluding one-time items in the October-December quarter, up from 71 cents per share a year earlier. Revenue rose 15% to $4.5 billion.

Upon U.S. Food and Drug Administration (“FDA”) approval, Teva will pay Royalty Pharma the total amount funded over five years, as well as low to mid-single digit royalties upon commercialization.